App-Quantinova.ai

2-O, 3-O-Desulfated Heparin (ODSH) Mitigates Chemotherapy-Induced Thrombocytopenia (CIT) by Blocking the Negative Paracrine Effect of Platelet Factor 4 (PF4) On Megakaryopoiesis

Samriddhi S Sharma - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Heparin

Targeting STAT5 in Leukemia Through Inhibition of Bromodomain Proteins

Sarah Walker - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Imatinib

Prolonged E. Coli Asparaginase Therapy Does Not Improve Significantly the Outcome for Children with Low and Average Risk Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL): Final Report of the EORTC-CLG Randomized Phase III Trial 58951

Stefan Suciu - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

Daunorubicin or Not During the Induction Treatment of Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): The Randomized Fralle 2000-A Protocol

Arnaud Petit - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute lymphoblastic leukemia

Allmercap

Transferred Donor-Derived WT1-Specific CD8+ T-Cell Clones After Hematopoietic Cell Transplantation Mediate Antileukemic Activity and Can Establish Persistent Responses without Toxicity to Normal Tissues in High-Risk Leukemia Patients

Gunnar B. Ragnarsson - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Recombinant Interleukin 21

Lineage-Specific Functions of LKB1 in CML and B Lymphoid Blast Crisis

Huimin Geng - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Tamoxifen

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

Joshua J Oaks - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Imatinib

Impact of Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry Pre and Post Transplantation, On Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Brent L. Wood - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

Thymocyte Reprogramming by the Scl, Lmo1 and Notch1 Oncogenes

Cedric Stevens Tremblay - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Cost-Effectiveness Analysis of Dexrazoxane in Preventing Long-Term Cardiac Dysfunction in Paediatric Patients With Haematological Malignancies

Ying Wang - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute lymphoblastic leukemia

ADR-529

The Prothrombotic Profile of BCR-ABL Inhibitors Ponatinib, Nilotinib and Imatinib

Rachel A Rigg - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Fibrinogen (IV)

Advanced glycation end-products and chronic inflammation in adult survivors of childhood leukemia treated with hematopoietic stem cell transplantation: possible role in the pathogenesis of cardiovascular late effects

Francesco Felicetti - European Congress of Endocrinology (ECE) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Asthma Donors

M. Kan - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Glucocorticoid

SUN-276 Acute Pancreatitis and Diabetic Ketoacidosis in an 8-Year-Old Following Induction Therapy for Pre-B Acute Lymphocytic Leukemia

Kathryn Schissler - Endocrine Society (ENDO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

PEG-asparaginase

Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach

M.Salama - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

Methadone hydrochloride

O-GlcNAcylation of c-Myc dynamically regulates pre-B cell proliferation

SUNG-KYUN PARK - American Association of Immunologists (AAI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Covalent adaptor synNotch and chimeric antigen receptors (CARs) for programmable antigen targeting

Jason Jakob Lomueller - American Association of Immunologists (AAI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Erbitux

New role of Epstein-Barr virus in pathogenesis of acute and chronic lymphocytic leukemia

Viktoryia Laurynenka - American Association of Immunologists (AAI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

The Ikaros1, IKZF1, risk locus for Acute Lymphoblastic Leukemia (ALL) at chromosome 7p12.2 regulates the expression of the FIGNL1 gene. (P1115)

Viktoryia Laurynenka - American Association of Immunologists (AAI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Developing a novel biologic for the treatment of high-risk B cell acute lymphoblastic leukemia (P1117)

Caleb Ruiz-Jimnez - American Association of Immunologists (AAI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Filters

2187 Abstracts